Get the Stockscreener App
10.96
0.09%
0.01
Pre-market:
9.01
-1.95
-17.79%
Gyre Therapeutics Inc stock is traded at $10.96, with a volume of 72,948.
It is up +0.09% in the last 24 hours and down -1.62% over the past month.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
See More
Previous Close:
$10.95
Open:
$11.07
24h Volume:
72,948
Relative Volume:
0.74
Market Cap:
$940.61M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
117.22
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+4.18%
1M Performance:
-1.62%
6M Performance:
-27.70%
1Y Performance:
-41.37%
1-Day Range:
$10.61
$11.36
1-Week Range:
$10.52
$11.36
52-Week Range:
$8.26
$26.37
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
10.96 | 940.61M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Gyre Therapeutics president Ma Songjiang sells shares for $42,860 - MSN
Gyre Therapeutics president Ma Songjiang sells shares for $42,860 By Investing.com - Investing.com Australia
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in December - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics president Songjiang Ma sells $11,156 in stock By Investing.com - Investing.com South Africa
Songjiang Ma Sells 1,057 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock - MarketBeat
Gyre Therapeutics president Songjiang Ma sells $11,156 in stock - Investing.com
Barclays PLC Has $116,000 Stock Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics president Ma Songjiang sells $22,336 in stock - Investing.com
Geode Capital Management LLC Has $3.81 Million Stock Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock - MarketBeat
Leadership Changes at Gyre Therapeutics Amid Strategic Shift - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3.2%Time to Sell? - MarketBeat
Gyre Therapeutics Reshapes Leadership: Appoints String Capital's Ping Zhang as Lead Director - StockTitan
Gyre Therapeutics president Ma Songjiang sells $49,600 in stock By Investing.com - Investing.com Australia
State Street Corp Grows Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics president Ma Songjiang sells $49,600 in stock - Investing.com
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.4% Following Insider Selling - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.4% After Insider Selling - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $50,553 in stock By Investing.com - Investing.com Australia
Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $25,400.00 in Stock - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $50,553 in stock - Investing.com India
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $48,399 in stock By Investing.com - Investing.com Australia
Gyre Therapeutics president Ma Songjiang sells $48,399 in stock - Investing.com India
Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Fmr LLC Takes $47,000 Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3%What's Next? - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $43,440 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $21,640.00 in Stock - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $43,440 in stock - Investing.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpHere's Why - MarketBeat
Gyre therapeutics president Ma Songjiang sells $44,851 in stock By Investing.com - Investing.com Australia
Gyre therapeutics president Ma Songjiang sells $44,851 in stock - Investing.com
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):